VGF-Derived Peptides: A New Antidepressant Target Class

Neuropeptides and Depression

7 days

A single infusion of the VGF-derived peptide TLQP-62 into the prefrontal cortex produced antidepressant effects lasting 7 days in mice, matching the sustained response seen with ketamine.

Jiang et al., Neuropsychopharmacology, 2019

Jiang et al., Neuropsychopharmacology, 2019

View as image

Most antidepressants target serotonin, norepinephrine, or dopamine. VGF-derived peptides work through an entirely different pathway: brain-derived neurotrophic factor (BDNF) and its receptor TrkB. The neuropeptide precursor VGF (the name is not an acronym) is a 617-amino-acid protein processed into several shorter peptides, the most studied of which is TLQP-62. In mice, TLQP-62 produced antidepressant effects comparable to fluoxetine but without engaging the serotonin system at all.^[1] For broader context on how neuropeptides fit into the depression landscape, see the neuropeptides and depression overview (the cluster pillar) and the articles on CRF and depression, substance P antagonists, and the neuropeptide theory of depression.

What Is VGF?

VGF is a neuropeptide precursor protein induced by nerve growth factor (NGF) and BDNF. The 617-amino-acid precursor is expressed throughout the brain, with high concentrations in the hippocampus, hypothalamus, and cerebral cortex. Like other neuropeptide precursors (such as POMC, which yields ACTH and beta-endorphin), VGF is cleaved by prohormone convertases into multiple bioactive peptides.

The best-characterized VGF-derived peptides include:

• TLQP-62: A 62-amino-acid C-terminal fragment. The name comes from its first four amino acids (Thr-Leu-Gln-Pro). This is the primary peptide studied for antidepressant effects.
• TLQP-21: A 21-amino-acid fragment derived from the same region. It activates complement receptor C3a receptor-1 on microglia, triggering immune signaling rather than neuronal growth.
• AQEE-30: A 30-amino-acid fragment that can be cleaved from TLQP-62.

The processing of VGF into these fragments is activity-dependent: neuronal firing, exercise, and antidepressant treatment all increase VGF expression and processing. This makes VGF a molecular link between brain activity and neuropeptide signaling.

The BDNF Connection: Why VGF Matters for Depression

The neurotrophic hypothesis of depression proposes that reduced BDNF signaling in key brain regions contributes to depressive symptoms, and that effective antidepressants work partly by restoring BDNF levels. VGF sits at a critical node in this pathway: BDNF induces VGF expression, and VGF-derived peptides in turn amplify BDNF signaling, creating a positive feedback loop.

Lin et al. (2014) demonstrated this directly. When TLQP-62 was microinjected into the hippocampal CA1 region of mice, it dose-dependently reduced immobility in the forced swim test and tail suspension test (standard rodent measures of depression-like behavior) without affecting locomotor activity. Chronic TLQP-62 infusion (21 days) upregulated BDNF expression and increased phosphorylation of both CREB (a transcription factor downstream of BDNF) and TrkB (the BDNF receptor).^[1]

The most revealing finding was the pharmacological blocking experiments. Pretreatment with K252a (a TrkB inhibitor) or tPA-STOP (which blocks tissue plasminogen activator, needed for BDNF maturation) completely abolished TLQP-62's antidepressant effects. But pretreatment with antagonists for serotonin receptors (5-HT1A, non-specific 5-HT), norepinephrine receptors (alpha-1, beta), or dopamine receptors (D2) had no effect whatsoever on TLQP-62's activity.^[1]

This is a clean dissociation: TLQP-62's antidepressant mechanism is entirely BDNF-dependent and entirely monoamine-independent. If this finding translates to humans, it would represent a genuinely novel antidepressant mechanism, distinct from SSRIs, SNRIs, and tricyclics. The neuropeptide theory of depression discusses why this matters for patients who do not respond to monoamine-targeting drugs.

Rapid-Acting Effects: The Ketamine Connection

One of the most striking features of TLQP-62 is its rapid-acting profile, similar to ketamine rather than traditional SSRIs (which take weeks to work).

Jiang et al. (2019) showed that VGF levels were reduced in Brodmann area 25 (part of the ventromedial prefrontal cortex, vmPFC) in postmortem brains from patients with major depressive disorder, and in the vmPFC of mice subjected to chronic restraint stress. Ketamine treatment increased VGF expression in mouse vmPFC, suggesting that part of ketamine's antidepressant mechanism involves VGF upregulation.^[2]

When TLQP-62 was infused directly into the vmPFC, it produced antidepressant-like behavior within hours. These effects persisted for 7 days after a single infusion. The sustained response required BDNF expression (VGF overexpression failed to produce antidepressant effects in mice with local BDNF gene deletion) and calcium mobilization through IP3 receptors and store-operated calcium channels.^[2]

VGF knockdown in the vmPFC increased susceptibility to stress and, critically, reduced ketamine's antidepressant efficacy. This positions VGF as a downstream mediator of ketamine's effects, not just an incidental correlate. If ketamine works partly through VGF, then targeting VGF directly could potentially replicate ketamine's rapid antidepressant action without its dissociative side effects.

Lv et al. (2018) mapped the downstream molecular pathway. In the prefrontal cortex, TLQP-62 activated TrkB, which in turn activated mTOR signaling, decreased BICC1 (a negative regulator of synaptic protein translation), and increased GluA1 AMPA receptor subunit expression and phosphorylation at Ser845. All of these effects were blocked by the TrkB antagonist ANA-12. This pathway, from TrkB through mTOR to synaptic protein synthesis, is the same cascade activated by ketamine and by exercise.^[5]

Beyond Depression: Neuroinflammation and Cognition

VGF-derived peptides do not only affect mood. Li et al. (2017) showed that TLQP-62 reversed the memory deficits, anxiety, and depression-like behavior caused by lipopolysaccharide (LPS) injection in mice. LPS is a bacterial endotoxin that triggers systemic inflammation, including neuroinflammation. The fact that TLQP-62 reversed LPS-induced behavioral changes suggests it may act at the intersection of neuroinflammation and mood regulation.^[3]

The mechanism again involved BDNF/TrkB signaling. LPS decreased hippocampal BDNF and TrkB phosphorylation, and TLQP-62 restored both. This is consistent with a model where inflammation suppresses neurotrophic signaling, causing cognitive and emotional deficits, and TLQP-62 counteracts this by directly boosting the BDNF pathway.^[3]

Moutinho et al. (2020) extended these findings to human cells. TLQP-62 promoted neurite outgrowth in SH-SY5Y cells (a human neuroblastoma line commonly used as a neuronal model), indicating that the peptide supports neuronal growth and connectivity. This neurotrophic effect is relevant to both depression (where reduced neuroplasticity is a proposed mechanism) and neurodegenerative diseases (where neuronal connections are lost).^[4]

VGF has also been identified as a potential biomarker. Reduced VGF levels have been found in cerebrospinal fluid from patients with Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Whether VGF reduction is a cause or consequence of neurodegeneration remains unclear, but the consistency across multiple disorders suggests VGF plays a fundamental role in brain health.

TLQP-21: The Immune-Active Fragment

While TLQP-62 acts primarily through neuronal BDNF signaling, the shorter fragment TLQP-21 has a different biology. It binds to complement receptor C3aR1 on microglia (the brain's resident immune cells) and triggers microglial chemotaxis, phagocytosis, and cytokine release. This immune-activating function may be relevant to Alzheimer's disease, where microglial clearance of amyloid plaques is a therapeutic goal, but it also means TLQP-21 could promote neuroinflammation in certain contexts.

The divergent functions of TLQP-62 and TLQP-21 illustrate a recurring theme in neuropeptide biology: a single precursor protein can generate fragments with opposing or complementary functions, and the biological outcome depends on which processing enzymes are active in a given cell type or brain region.

Limitations and the Path Forward

All published VGF antidepressant data is preclinical. No human trials of TLQP-62 or any VGF-derived peptide have been conducted. Several challenges stand between the mouse data and a clinical drug:

Delivery. TLQP-62 is a 62-amino-acid peptide that does not cross the blood-brain barrier when administered peripherally. The preclinical studies used direct brain infusion. Developing a systemically administered form would require either a delivery technology (nanoparticles, intranasal route, or a small-molecule mimetic of TLQP-62's TrkB-activating effect) or a prodrug strategy.

Selectivity. VGF-derived peptides have effects beyond mood regulation, including metabolic effects (VGF knockout mice are lean and hypermetabolic), immune modulation (through TLQP-21), and potential effects on pain signaling. A systemically administered VGF peptide could have off-target effects.

Species translation. Forced swim test and tail suspension test results in mice do not reliably predict antidepressant efficacy in humans. Many compounds that looked promising in these assays failed in clinical trials. The strongest translational evidence is the finding that VGF levels are reduced in Brodmann area 25 of human MDD patients, which establishes disease relevance in the target tissue.^[2]

Competition. The rapid-acting antidepressant space already has ketamine and esketamine (Spravato). Any VGF-based therapy would need to demonstrate advantages over these existing options, whether in efficacy, duration, side effect profile, or route of administration.

Despite these hurdles, the VGF pathway offers something genuinely new: a neuropeptide-based antidepressant mechanism that is completely independent of monoamine neurotransmission. For the estimated 30% of depression patients who do not respond to serotonin-targeting drugs, alternative mechanisms like BDNF/TrkB activation through VGF peptides represent a biologically rational next frontier. The Selank and Dihexa articles cover other neuropeptides being investigated for cognitive and mood effects.

The Bottom Line

VGF-derived peptides, particularly the 62-amino-acid fragment TLQP-62, represent a novel antidepressant mechanism that works through BDNF/TrkB signaling rather than serotonin, norepinephrine, or dopamine. In mice, TLQP-62 produced rapid-acting, sustained antidepressant effects comparable to ketamine, and VGF levels are reduced in the prefrontal cortex of human MDD patients. The peptide also reverses neuroinflammation-induced cognitive deficits and promotes neurite outgrowth. All data is preclinical, and significant delivery and translation challenges remain before any VGF-based therapy reaches human testing.

Frequently Asked Questions

What is VGF peptide?

VGF is a 617-amino-acid neuropeptide precursor protein induced by nerve growth factor and BDNF. It is processed into several shorter bioactive peptides including TLQP-62 (62 amino acids), TLQP-21 (21 amino acids), and AQEE-30 (30 amino acids). VGF is expressed throughout the brain with high concentrations in the hippocampus and prefrontal cortex. The name VGF is not an acronym.

How does TLQP-62 work as an antidepressant?

TLQP-62 activates BDNF/TrkB/CREB signaling in the hippocampus and prefrontal cortex. Lin et al. (2014) showed that its antidepressant effects were completely blocked by TrkB inhibition but unaffected by serotonin, norepinephrine, or dopamine receptor antagonists. It also activates mTOR signaling, increases synaptic protein expression, and promotes AMPA receptor phosphorylation (Lv et al., 2018).

Is VGF reduced in people with depression?

Jiang et al. (2019) found that VGF levels were reduced in Brodmann area 25 (part of the ventromedial prefrontal cortex) in postmortem brains from patients with major depressive disorder. VGF was also reduced in the vmPFC of mice subjected to chronic restraint stress, and ketamine treatment restored VGF expression in mice.

How is TLQP-62 different from SSRIs?

SSRIs work by blocking serotonin reuptake, increasing serotonin availability in synapses. TLQP-62 does not involve serotonin at all. It activates BDNF/TrkB signaling directly, promoting neuronal growth and synaptic protein synthesis. Unlike SSRIs, which take weeks to work, TLQP-62 produced antidepressant effects within hours in mouse studies and sustained effects for 7 days after a single dose.

Is TLQP-62 available as a treatment?

TLQP-62 is not available as a treatment as of 2026. All published data comes from preclinical studies in mice and cell cultures. The peptide does not cross the blood-brain barrier, and preclinical studies used direct brain injection. Significant drug development work would be needed before any VGF-based therapy could reach human clinical trials.

What is the connection between VGF and ketamine?

Jiang et al. (2019) showed that ketamine increased VGF expression in the ventromedial prefrontal cortex, and that VGF knockdown reduced ketamine's antidepressant efficacy. This suggests VGF is a downstream mediator of ketamine's rapid antidepressant effects. Both TLQP-62 and ketamine activate the TrkB/mTOR pathway and increase synaptic protein synthesis.